Skip to main content
Filing year 2024

The National Immunotherapy Cancer

Flemington, New Jersey·EIN 22-3067246·NTEE H30Z · Medical Research·3
Total revenue
$390k
Total assets
$1.2M
Total expenses
$100k
Reported officers
4
Mission

TO PROVIDE GRANTS TO SECTION 501C3 ORGANIZATIONS THAT ADVANCE AND IMPROVE SCIENTIFIC RESEARCH IN IMMUNOTHERAPY AND TO ORGANIZATIONS THAT PROMOTE, ADVANCE AND IMPROVE EDUCATION AND SUPPORT CANCER PATIENTS

Reported officers (all unpaid)

No paid executives reported in 2024. The National Immunotherapy Cancer reported 4 unpaid officers and board members on its 990.

Director
Director
President
Treasurer
Financial trend

Revenue and expenses over time

The National Immunotherapy Cancer reported revenue and expenses across 2 filing years.

RevenueExpenses
$151k
$98k
2023
$390k
$100k
2024
Total revenue and total expenses from IRS Form 990 filings.
Sector benchmark

What Medical Research executives earn

The National Immunotherapy Cancer reported no executive compensation in its latest filing. For context, the highest-paid executive at a comparable medical research organization nationwide earns a median of $120,264.

25th percentile
$48k
Median
$120,264
75th percentile
$252k
90th percentile
$466k

These are medical research sector-wide figures, not this organization's reported pay. Based on 1,118 organizations across 1,118 filings (2020 – 2024).

See full Medical Research compensation data
FAQ

Common questions about The National Immunotherapy Cancer

What are The National Immunotherapy Cancer's revenue and expenses?

In 2024, The National Immunotherapy Cancer reported $390k in total revenue and $100k in total expenses on its IRS Form 990.

Free, forever
Build lists. Save your benchmarks.
A free Lucido account lets you build lists of nonprofits and save your search filters. No credit card.
Already a member? Sign in
Build a benchmark

Compare any role, sector, or revenue band

Build your own benchmark from millions of reported positions.